A drug trial that worked too well to continue
A drug trial that worked too well to continue.
Praxis Precision Medicines announced on Thursday that its Phase 2 EMBOLD trial for relutrigine — a sodium channel blocker being tested in children with severe developmental and epileptic encephalopathies linked to SCN8A and SCN2A gene mutations — has been stopped early. A data monitoring board recommended stopping the study for efficacy. No numerical data was disclosed. Praxis will present findings at the American Epilepsy Society conference in December and has an FDA meeting scheduled to discuss next steps.
The decision to stop a trial early for efficacy is uncommon and structurally significant. It means the independent monitors saw enough evidence of benefit after an interim analysis that continuing to give some patients placebo would be unethical or scientifically indefensible. That does not guarantee approval, but it is a different kind of signal than a positive readout press release that omits the magnitude of the effect.
Relutrigine is an oral small molecule that modulates sodium channels by inhibiting persistent currents — a mechanism Praxis identifies as a major driver of symptoms in severe developmental epilepsies. Previous cohorts had shown the drug was well-tolerated, produced biomarker changes consistent with sodium channel modulation, and led to what the company called robust improvements in motor seizures. The EMBOLD stop is the clinical translation of that earlier signal.
Truist Securities projects relutrigine could reach $650 million in peak U.S. sales by 2037, with the caveat that the estimate could be conservative depending on how broadly the drug gets used across the DEE landscape. That projection is for the SCN2A and SCN8A indication alone. If the FDA allows broader labeling or additional DEE subtypes, the number could move.
Also Thursday, Praxis completed a pre-NDA meeting with the FDA for ulixacaltamide, a calcium channel inhibitor for essential tremor. The agency agreed on the contents of the application, and filing is expected early next year. Jefferies has modeled 70% plus probability of approval and projected peak sales above $2.5 billion. Truist is more bullish, projecting north of $3 billion in the U.S. by around 2040.
Two pipeline updates, both positive, both heading toward regulators. Praxis has no approved products. The epilepsy program is the more clinically urgent story — children with SCN8A and SCN2A mutations have limited options and significant mortality. The essential tremor program is the financial floor. Together they define a company that is either on its way to becoming a takeout target or on its way to a commercial-stage biotech. The EMBOLD stop moves that calculation in one direction.